SIR 2024
Interventional Oncology
Thomas Le, MD, MS
Associate Professor
Olive View-Ucla Medical Center
Financial relationships: Full list of relationships is listed on the CME information page.
Tze Min Wah, MD, PhD
Interventional Radiologist
St. James University Hospital, United Kingdom
Disclosure information not submitted.
Nicos Fotiadis, MD, FRCR, EBIR
Interventional Radiologist
Royal Marsden NHS Foundation Trust, United Kingdom
Disclosure information not submitted.
Bruno C. Odisio, MD, FSIR (he/him/his)
Interventional Radiologist
MD Anderson Cancer Center
Disclosure information not submitted.
Kevin Anton, MD, PhD (he/him/his)
Assistant Professor of Radiology
Thomas Jefferson University
Disclosure information not submitted.
Chang Jin Yoon, MD, Ph D
Professor
Seoul National University Bundang Hospital, Republic of Korea
Disclosure information not submitted.
A multicenter, single-arm registry will enroll up to 1,500 adult patients undergoing MWA using the NEUWAVE™ MWA System with a follow-up of 5 years. Herein, we summarize preliminary data for the initial 801 patients treated at 27 global sites from August 2010 through June 2023. Primary endpoints include technical success (TS), technique efficacy (TE), and local tumor progression (LTP), based on clinical sites’ standard-of-care imaging.
Results:
A total of 801 patients (70.8% male; 66 years median age [range 23-89]) underwent 946 MWA procedures (initial and re-ablation, as needed). The mean number of ablation sessions per patient was 1.18. Single vs multiprobe approaches were assessed in patients with one lesion treated at the initial ablation session (642/801, 80.1%). Lesion size was categorized as < 3 cm (n=548), 3 to < 5 cm (n=88), and > 5 cm (n=6). Given the small number of lesions > 5 cm in the current dataset, endpoints (TS, TE, LTP) for this group are not reported.
Outcomes data (TS, TE, and LTP) were similar for single vs multiple probe use for < 3 cm tumors (Table). Higher TS and TE rates were observed for multiple probes compared to single probes in the 3 cm to < 5 cm group. No differences in LTP between single and multiple probes were observed in this tumor size group.
Procedure-related non-serious and serious AEs occurred in 38.6% (175/453) and 9.7% (44/453) of patients treated with single probes, respectively, and 32.8% (62/189) and 11.6% (22/189) of patients treated with multiple probes, respectively.
Conclusion:
Preliminary data from NOLA suggest that MWA using multiple probes is a more effective approach than the use of a single probe for the treatment of large liver tumors. Larger NOLA cohorts and longer follow-up times will provide further real-world insights on the relationship between single vs multiprobe ablation approaches and lesion size to improve short- and long-term local oncological MWA outcomes.